Mukhopadhyay S, Baer S, Blanshard J, Coleman M, Carswell F
Department of Child Health, University of Bristol, UK.
J Antimicrob Chemother. 1993 Mar;31(3):429-36. doi: 10.1093/jac/31.3.429.
A deterioration in pulmonary function is a common problem in patients with cystic fibrosis. One strategy which might help to arrest this process is the administration of aminoglycosides by nebulizer in dosages which greatly exceed those which are normally given parenterally. Ten patients (4-19 years of age) with cystic fibrosis underwent evoked response audiometry at regular intervals following a 400 mg dose of nebulized tobramycin; the concentrations of tobramycin in samples of blood taken at the same time intervals were also determined. No significant abnormalities in the audiometric investigations were detected. The relationship between shifts in vestibulocochlear potentials and long-term ototoxic sequelae in patients receiving aminoglycosides via a nebulizer requires further evaluation.
肺功能恶化是囊性纤维化患者的常见问题。一种可能有助于阻止这一过程的策略是通过雾化器给予大大超过通常肠胃外给药剂量的氨基糖苷类药物。10名年龄在4至19岁之间的囊性纤维化患者在接受400毫克雾化妥布霉素剂量后定期进行诱发反应听力测定；同时还测定了在相同时间间隔采集的血样中妥布霉素的浓度。听力检查未发现明显异常。通过雾化器接受氨基糖苷类药物治疗的患者，其前庭蜗电位变化与长期耳毒性后遗症之间的关系需要进一步评估。
